Pharnext (PNEXF)

[nuketheshorts]

Developed over the last 30 years, this concept is a new paradigm recognized by internationally renowned scientists, including several Nobel laureates. PLEOTHERAPY differs from monotherapy, the principle of which is to target a single therapeutic target by allowing the treatment of several targets at the same time thanks to PLEODRUG ™ . These are low-dose, synergistic combinations of drugs already used for other diseases with a known safety profile, and many benefits: an excellent safety and efficacy profile as well as extensive and robust intellectual property. Moreover, the use of already approved molecules considerably reduces the duration and cost of development of a PLEODRUG compared to a conventional drug.

Pharnext's goal is to become the champion of repositioning and combinations. We have chosen, to demonstrate the relevance of this approach, to start working on diseases with high medical needs that have not received satisfactory treatment to date: Charcot-Marie-Tooth type 1A disease and Alzheimer.